NASDAQ/AIM: MTFB April 26, 2018
Important Information The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation (together, the "Presentation"), has been prepared by Motif Bio plc (the "Company"). The information in the Presentation is not intended to form the basis of any contract. By attending (whether in person or by telephone) or reading the Presentation, you agree to the conditions set out below. The Presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares or other securities of the Company, nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement to enter into, any contract whatsoever relating to any securities. The Presentation is provided for general information only and does not purport to contain all the information that may be required to evaluate the Company. The information in the Presentation is provided as at the date of the Presentation (unless stated otherwise) and is subject to updating, completion, revision and further verification. No reliance may be placed for any purpose whatsoever on the information or opinions contained or expressed in the Presentation or on the accuracy, completeness or fairness of such information and opinions. To the extent permitted by law or regulation, no undertaking, representation or warranty or other assurance, express or implied, is made or given by or on behalf of the Company, or any of its parent or subsidiary undertakings or the subsidiary undertakings of any such parent undertakings or any of their respective directors, officers, partners, employees, agents, affiliates, representatives or advisors, or any other person, as to the accuracy, completeness or fairness of the information or opinions contained in the Presentation. Save in the case of fraud, no responsibility or liability is accepted by any such person for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred, however arising, directly or indirectly, from any use of, as a result of the reliance on, or otherwise in connection with, the Presentation. In addition, no duty of care or otherwise is owed by any such person to recipients of the Presentation or any other person in relation to the Presentation. All statements pertaining to future financial and/or operating results, future growth in research, clinical development, and potential opportunities for the Company and its products, along with other statements about the future expectations, beliefs, goals, plans or prospects expressed by the presenter(s) constitute forward- looking statements. Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forwar d-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achi evements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. The Company believes that these factors include, but are not limited to, (i) the timing, progress and the results of clinical trials for the Company’s product candidates, (ii) the timing, scope or likelihood of regulatory filin gs and approvals for the Company’s product candidates, (iii) the Company’s ability to successfully commercialize its product candidates, (iv) the Company’s ability to effectively market any product candidates that receive regulatory approval, (v) the Company’s commercialization, marketing and manufacturing capabilities and strategy, (vi) the Company’s expectation regarding the safety and efficacy of its product candidates, (vii) the potential clinical utility and benefits of the Company’s product candidates, (viii) the Company’s ability to advance its prod uct candidates through various stages of development, especially through pivotal safety and efficacy trials, (ix) the Company’s estimates regarding the potential market opportunity for its p rod uct candidates, and (x) the factors discussed in the “Risk Factors” section in the Company’s Annual Report on Form 20 -F filed with the SEC on May 1, 2017, which is available at www.sec.gov and in the "Principal Risks and Uncertainties" section in our UK published Annual Report & Accounts. The Company undertakes no obligation to update or revise any forward-looking statements. Other than in accordance with our legal and regulatory obligations (including under the UK Financial Conduct Authority’s Listing Rules and the Disclosure Guidance and Transparency Rules, and the EU Market Abuse Regulation), the Company does not undertake to update forward-looking statements to reflect any changes in its expectations with regard thereto or any changes in events, conditions or circumstances on which any such statement is based. Certain industry and market data contained in this Presentation has come from third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. Although the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the industry and market data contained in this Presentation comes from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Any information contained in this Presentation relating to the Company or its share price or the yield on its shares are not guarantees of, and should not be relied upon as an indicator of, future performance. Nothing in this Presentation should be construed as a profit forecast or profit estimate. 2
Motif Bio: Helping to Solve the Antibiotic Crisis Antibiotic candidate, underutilized MOA, targeted Gram- Iclaprim positive spectrum (MRSA), rapidly bactericidal*, <2% excreted via kidneys, fixed dose**, lung concentration REVIVE-1 Positive Phase 3 data – Q2 2017 Clinical Development REVIVE-2 Positive Phase 3 data – Q3 2017 Expected to begin HABP/VABP Ph 3 in 2018*** 3.6M hospitalized ABSSSI patients 1 , up to 26% with renal Significant Commercial Opportunity impairment 2 ; 1.4M hospitalized HABP patients, 40% G+ QIDP & Fast Track designation; Rolling submission initiated; NDA Submission Q2 2018 Priority Review expected upon acceptance of NDA S. aureus lung infections in patients with cystic fibrosis (CF) Orphan Disease Program - preclinical Development, regulatory, manufacturing, financial, Experienced Team commercial expertise MRSA – methicillin-resistant Staphylococcus aureus ; ABSSSI – acute bacterial skin & skin structure infections; HABP – hospital acquired bacterial pneumonia; VABP – ventilator associated bacterial pneumonia; QIDP = Qualified Infectious Disease Product; * in vitro; **40mg for patients with moderate hepatic impairment ; https://www.ncbi.nlm.nih.gov/pubmed/?term=huang+db+2017; *** subject to funding 1 Estimated number of patients hospitalized with ABSSSI/HAP in U.S. in 2015 2 Halilovic et al, Journal of Infection (2012) 65, 128-134 (n = 106), evaluable patients hospitalized with cellulitis/cutaneous abscess. (This study, using a sample size of n=106 evaluable patients, gave a rate of 26% of evaluable patients with renal impairment (evaluable patients were considered to be those who had at least one documented visit with their physician after hospitalization and the visit included a 3 clinical evaluation of their cellulitis)
Recommend
More recommend
